Form 4: Agenus Inc. Director Susan B. Hirsch Reports Stock Option Award

Director Susan B. Hirsch reports the acquisition of stock options in Agenus Inc. on February 5, 2024.

Summary

• Susan B. Hirsch, a director of Agenus Inc., filed a Form 4 on April 22, 2024, reporting a transaction.
• On February 5, 2024, Hirsch was awarded stock options for 5,000 shares of Agenus Inc. common stock with an exercise price of $12.60.
• These options vest on February 5, 2025, and expire on February 5, 2034.
• The stock options were granted prior to the 1 for 20 reverse stock split, representing 100,000 Stock Options with an exercise price of $0.63.
• Following the reported transaction, Hirsch directly owns 5,000 derivative securities.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, indicating confidence in the company's future performance. The sentiment is neutral to positive.

Positives

• The granting of stock options to a director aligns their interests with those of the shareholders.
• The vesting schedule incentivizes continued service and contribution to the company's success.

Future Outlook

The document does not contain specific forward-looking statements beyond the vesting and expiration dates of the stock options.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, aligning management's interests with shareholder value creation.

Comparison to Industry Standards

• Stock option grants are a standard component of compensation packages for directors in publicly traded companies, particularly in the biotech sector.
• The vesting schedule of one year is fairly typical, incentivizing continued service.
• Comparable companies such as BioNTech or Moderna also utilize stock options as part of their executive compensation packages.

Stakeholder Impact

• The stock option grant could positively impact shareholders by aligning the director's interests with the company's long-term success.
• The director is incentivized to increase shareholder value.

Key Dates